亿帆医药：注射用硫酸多黏菌素B获药品注册证书

Core Viewpoint - Yifan Pharmaceutical (002019) announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for injectable colistin sulfate from the National Medical Products Administration on January 22, 2026, which is intended for treating severe infections caused by carbapenem-resistant Gram-negative bacteria in adult patients [1]. Group 1 - The drug injectable colistin sulfate is primarily used to treat severe infections caused by carbapenem-resistant Gram-negative bacteria, including meningitis and bacteremia caused by sensitive strains of Pseudomonas aeruginosa [1].